Stock TARS TARSUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Tarsus Pharmaceuticals, Inc.

Equities

TARS

US87650L1035

Market Closed - Nasdaq
Other stock markets
 01:30:00 22/06/2024 am IST 		5-day change 1st Jan Change
26.08 USD -1.25% Intraday chart for Tarsus Pharmaceuticals, Inc. -15.82% +28.79%
10/06 Transcript : Tarsus Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:00 PM
31/05 Certain Restricted Stock Units of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024. CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q1 Revenue $27.6M, vs. Street Est of $17.9M
MT
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals
AN
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc
CI
Tarsus Pharmaceuticals' Q4 Net Loss Widens, Revenue Increases
MT
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q4 Revenue $13.1M, vs. Street Est of $5.9M
MT
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Tarsus Announces Positive Topline Results from Carpo, A Phase 2A Proof-Of-Concept ?Tick-Kill? Trial Evaluating Tp-05 for the Prevention of Lyme Disease
CI
Tarsus Pharmaceuticals, Inc. Announces Positive Topline Results from the Ersa Phase 2A Clinical Trial Evaluating Tp-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
CI
Tarsus Pharmaceuticals Rose 5% in After-Hours Activity Thursday After Q3 Sales Beat Market Expectations
MT
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Reports Q3 Revenue $1.9M, vs. Street Est of $0.4M
MT
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Tarsus Pharmaceuticals, Inc. Announces Availability of XDEMVY? (Lotilaner Ophthalmic Solution) 0.25%
CI
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
LianBio, Tarsus Pharmaceuticals Get US FDA Approval For Xdemvy in Treating Eye Disease Demodex Blepharitis
MT
FDA Approves Tarsus Pharmaceuticals, Inc.'s XDEMVY(TM) (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex blepharitis
CI
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TARS Stock
  4. News Tarsus Pharmaceuticals, Inc.
  5. Highlights